Literature DB >> 14702129

Ocular side effects associated with bisphosphonates.

Frederick W Fraunfelder1.   

Abstract

Bisphosphonates are used to inhibit bone resorption in postmenopausal women and in the management of hypercalcemia of malignancy. Recently, some drugs within this class of medicines have been proven to cause scleritis. Prior to this, bisphosphonates had been reported to cause a variety of ocular side effects, most of which are inflammatory. This review discusses the many different medicines called bisphosphonates and highlights the ocular side effect profile of each. In cases where information on dechallenge is provided, all the ocular side effects resolved after discontinuation of the medication. Recognition of adverse ocular events in association with bisphosphonate therapy should alert clinicians to the need for ophthalmic evaluation and the consideration of discontinuation of therapy in all cases of scleritis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14702129     DOI: 10.1358/dot.2003.39.11.799461

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  4 in total

Review 1.  Ocular side effects of bisphosphonates: A case report and literature review.

Authors:  Meredith McKague; Derek Jorgenson; Kelly A Buxton
Journal:  Can Fam Physician       Date:  2010-10       Impact factor: 3.275

Review 2.  Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.

Authors:  V Peponis; V C Kyttaris; S E Chalkiadakis; S Bonovas; N M Sitaras
Journal:  Lupus       Date:  2010-02-09       Impact factor: 2.911

3.  Therapeutic effect of oral bisphosphonates on choroidal neovascularization in the human eye.

Authors:  Shigeru Honda; Takayuki Nagai; Naoshi Kondo; Masahide Fukuda; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  J Ophthalmol       Date:  2010-07-25       Impact factor: 1.909

Review 4.  Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations.

Authors:  John Sunyecz
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.